Mobilisation et Résultats Après Fermeture Veineuse (MOVE)
MOVE - Mobilisation et Résultats Après Fermeture VEineuse - Un Registre Prospectif des Résultats/Utilisations/Preuves en Conditions Réelles pour le Dispositif de Fermeture Vasculaire VEineux MYNX CONTROL™ 6F-12F
The primary objective of this post-market registry is to collect real-world outcomes and evaluate usage practice of MYNX CONTROL™ VENOUS (MCV) Vascular Closure Device (VCD) 6F-12F in sealing femoral venous access sites in patients who have undergone endovascular procedures in a real-world setting.
Aperçu de l'étude
Statut
Statut
Les conditions
Les conditions
Intervention / Traitement
Intervention / Traitement
Description détaillée
The study is a single-arm, prospective, multi-center, observational, real-world registry of venous access site closures utilizing MYNX CONTROL™ VENOUS VCD 6F-12F following endovascular procedures. The study will enroll approximately 300 subjects in approximately 15 study sites in the United States.
Type d'étude
Type d'étude
Inscription (Réel)
Inscription
Contacts et emplacements
Lieux d'étude
-
-
California
-
Los Angeles, California, États-Unis, 90048
- Cedars Sinai Medical Center
-
Palo Alto, California, États-Unis, 94304
- Stanford University School of Medicine
-
-
Colorado
-
Littleton, Colorado, États-Unis, 80210
- South Denver Cardiology
-
-
Florida
-
Orlando, Florida, États-Unis, 32803
- AdventHealth Orlando
-
-
Illinois
-
Glenview, Illinois, États-Unis, 60026
- Glenbrook Hospital
-
-
Kansas
-
Overland Park, Kansas, États-Unis, 66211
- KC Heart and Rhythm Institute
-
-
Kentucky
-
Lexington, Kentucky, États-Unis, 40503
- Baptist Health Lexington
-
-
North Carolina
-
Raleigh, North Carolina, États-Unis, 27607
- North Carolina Heart & Vascular Research, LLC
-
-
Washington
-
Bellevue, Washington, États-Unis, 98004
- Overlake Medical Center
-
-
Critères de participation
Critère d'éligibilité
Critère d'éligibilité
Âges éligibles pour étudier
- Enfant
- Adulte
- Adulte plus âgé
Accepte les volontaires sains
Sexes éligibles pour l'étude
Méthode d'échantillonnage
Population étudiée
The study includes patients who undergo catheter-based procedures utilizing 6F to 12F inner diameter procedural sheaths, with single or multiple venous access sites in one or both limbs, and have their venous access site(s) closed with MYNX CONTROL™ VENOUS VCD 6F-12F per IFU.
La description
Inclusion Criteria
- Able and willing to provide informed consent and to complete a follow-up visit at 14 ± 7 days post-procedure.
- Individuals undergoing catheter-based procedures utilizing 6F to 12F inner diameter procedural sheaths, with single or multiple venous access sites in one or both limbs.
- Individuals who are candidates to have their venous access site(s) closed with MYNX CONTROL™ VENOUS VCD 6F-12F per IFU.
- At the time of enrollment, the Investigator deems the subject a candidate for same-day discharge (SDD) per standard of care (no procedure related events/complications e.g., no new pericardial effusion, post-procedure diuresis not needed, etc.).
Exclusion Criteria
- Presence of bruit, palpable aneurysm, significant candida or groin infection.
- Prior to closure, presence of hematoma in the accessed limb.
- Currently involved in any other clinical trial that may interfere with the outcomes of this study as determined by the Investigator.
- Planned use of other closure devices or techniques other than MYNX CONTROL™ VENOUS VCD 6F-12F.
- Life expectancy <12 months.
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Modèles d'observation: COHORT
- Perspectives temporelles: PROSPECTIVE
Nombre de groupes / cohortes
Cohortes et interventions
Groupe / CohorteGroupe / Cohorte |
Intervention / TraitementIntervention / Traitement |
|---|---|
|
MCV VCD Treatment
Subjects who undergo catheter-based procedures utilizing 6F to 12F inner diameter procedural sheaths, with single or multiple venous access sites in one or both limbs, and have their venous access site(s) closed with MYNX CONTROL™ VENOUS VCD 6F-12F per IFU. |
The MYNX CONTROLTM VENOUS (MCV) Vascular Closure Device (VCD) 6F-12F is indicated for use to seal femoral venous access sites while reducing times to hemostasis and ambulation in patients who have undergone diagnostic or interventional endovascular procedures utilizing 6F to 12F procedural sheaths, with single or multiple access sites in one or both limbs. MCV VCD is designed to achieve femoral vein hemostasis via delivery of the GRIP TECHNOLOGY™ sealant (an extravascular, water-soluble synthetic hydrogel), using a balloon catheter in conjunction with a standard procedural sheath. The sealant is made of a polyethylene glycol (PEG) material which expands upon contact with subcutaneous fluids to seal the venotomy and is resorbed by the body within 30 days. The MCV VCD is supplied with a 10ml locking syringe used for balloon inflation and deflation. The catheter shaft has a silicone lubricant to facilitate insertion and withdrawal into compatible sheaths. |
Que mesure l'étude ?
Principaux critères de jugement
Principaux critères de jugement
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Rate of patients with same day discharge (SDD) and without subsequent hospitalization/intervention for access-site complications
Délai: From time of index procedure through end of following day (within 48 hours)
|
Rate of patients who successfully received a study device at all access sites and had SDD without subsequent hospitalization/intervention for access-site complications either same day post-discharge or the next day |
From time of index procedure through end of following day (within 48 hours)
|
|
Rate of access-site complications
Délai: From time of study device introduction at first access site through 14 days post-procedure
|
Rate of access-site complications, assessed per standard of care, through 14 days post-procedure, including:
|
From time of study device introduction at first access site through 14 days post-procedure
|
Autres mesures de résultats
Autres mesures de résultats
Mesure des résultats |
Description de la mesure |
Délai |
|---|---|---|
|
Time to Ambulation
Délai: From end of index procedure until time before hospital discharge (usually within ~24 hours of procedure)
|
Defined as elapsed time (in hours) between removal of the final MCV VCD and when subject stands and walks 20 feet without evidence of rebleeding from any femoral venous access site. |
From end of index procedure until time before hospital discharge (usually within ~24 hours of procedure)
|
|
Time to Discharge
Délai: From end of index procedure until time of hospital discharge (usually within ~24 hours of procedure)
|
Defined as the elapsed time (in minutes) between removal of the final MCV VCD and when the subject is discharged from the hospital, as recorded on the discharge order. |
From end of index procedure until time of hospital discharge (usually within ~24 hours of procedure)
|
|
Time to Hemostasis
Délai: From time of index procedure until time before hospital discharge (usually within ~24 hours of procedure)
|
Defined as elapsed time (in minutes) between removal of each MCV VCD and first observed and confirmed venous hemostasis (per access site analysis). |
From time of index procedure until time before hospital discharge (usually within ~24 hours of procedure)
|
|
SDD sustained MCV VCD success
Délai: From end of index procedure through 14 days post-procedure
|
Defined as the proportion of subjects who did not require hospital intervention within 14 days post-procedure due to access site-related complications |
From end of index procedure through 14 days post-procedure
|
|
Device success evaluated at the end of the procedure
Délai: End of index procedure
|
Defined as the ability to deploy the delivery system and deliver the PEG component to achieve hemostasis at each access site |
End of index procedure
|
|
Procedural Success
Délai: From end of index procedure through 14 days post-procedure
|
Defined as the attainment of final hemostasis at all venous access sites without major venous access site closure-related complications through 14 days |
From end of index procedure through 14 days post-procedure
|
|
Procedural Time
Délai: Index procedure
|
Defined as time of first sheath insertion until the time of removal of final MCV VCD. |
Index procedure
|
|
Recovery room time
Délai: From time of transfer to recovery room post-discharge to time of discharge (usually within ~24 hours of procedure)
|
Defined as elapsed time (in minutes) between when the subject is transferred to recovery and when the subject is discharged from the hospital, as recorded on the discharge order. |
From time of transfer to recovery room post-discharge to time of discharge (usually within ~24 hours of procedure)
|
|
Analysis of Cost Effectiveness - Comprehensive summary of clinical outcomes, resource utilization, economic proxies, patients reported outcomes and CPT codes
Délai: From start time of index procedure through 14 days post-procedure
|
An analysis of cost effectiveness will be performed based on a summary of key clinical outcomes, resource utilization, economic proxies, patients reported outcomes and CPT codes |
From start time of index procedure through 14 days post-procedure
|
|
Incidence of urinary catheter usage
Délai: From start time of index procedure through end time of index procedure
|
Number/rate of patients with urinary catheters used during the procedure |
From start time of index procedure through end time of index procedure
|
|
Incidence of protamine usage
Délai: From start time of index procedure through end time of index procedure
|
Incidence of protamine usage during the procedure |
From start time of index procedure through end time of index procedure
|
|
Medication Usage
Délai: From pre-procedure though study exit/follow-up visit (14 +/- 7 days post-procedure)
|
Rate of patients who are administered anti-platelet, anti-coagulant, anti-thrombotic, local anesthetic, protamine or pain medication |
From pre-procedure though study exit/follow-up visit (14 +/- 7 days post-procedure)
|
Collaborateurs et enquêteurs
Parrainer
Parrainer
Collaborateurs
Collaborateurs
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude (Réel)
Début de l'étude
Achèvement primaire (Réel)
Achèvement primaire
Achèvement de l'étude (Réel)
Achèvement de l'étude
Dates d'inscription aux études
Première soumission
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première soumission répondant aux critères de contrôle qualité
Première publication (Réel)
Première publication
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Réel)
Dernière mise à jour publiée
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Dernière vérification
Plus d'information
Termes liés à cette étude
Mots clés
Autres numéros d'identification d'étude
Autres numéros d'identification d'étude
- P25-8302
Plan pour les données individuelles des participants (IPD)
Prévoyez-vous de partager les données individuelles des participants (DPI) ?
Informations sur les médicaments et les dispositifs, documents d'étude
Étudie un produit pharmaceutique réglementé par la FDA américaine
Étudie un produit d'appareil réglementé par la FDA américaine
produit fabriqué et exporté des États-Unis.
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .